Surmodics (SRDX) to Release Earnings on Thursday

Surmodics (NASDAQ:SRDX) is expected to release its earnings data before the market opens on Thursday, February 6th. Analysts expect Surmodics to post earnings of ($0.12) per share and revenue of $33.37 million for the quarter.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.14. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%. The firm had revenue of $33.23 million during the quarter, compared to analysts’ expectations of $30.69 million. On average, analysts expect Surmodics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surmodics Trading Down 0.0 %

Shares of SRDX stock opened at $35.78 on Thursday. The company has a current ratio of 3.96, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. Surmodics has a 12-month low of $25.17 and a 12-month high of $42.44. The stock has a market capitalization of $511.30 million, a P/E ratio of -44.17 and a beta of 1.21. The firm’s 50 day moving average is $38.88 and its 200 day moving average is $39.23.

Insider Buying and Selling

In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the sale, the chief financial officer now directly owns 70,350 shares of the company’s stock, valued at $2,774,604. This trade represents a 9.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on SRDX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a report on Thursday, November 7th. StockNews.com assumed coverage on Surmodics in a research note on Sunday. They set a “hold” rating for the company. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).